Pfizer released initial clinical data from its Phase 1b gene therapy study for Duchenne muscular dystrophy. While these results did not necessarily live up to expectations, there is a winner in this.
These are the top analyst upgrades and downgrades for Friday, June 21, 2019. There are many stocks to Buy, including NLY, FISV, KEY, PSX and others.
Spark Therapeutics shares more than doubled in Tuesday’s session as the result of its pending acquisition. However, the root of the buyout was its gene therapy, which could drive more acquisitions in…
Chris Lange Many Wall Street firms are issuing their top picks and listing their favorite sectors and trends to consider for the year ahead. Credit Suisse is one of those firms.
After a big stock market sell-off and a subsequent snap-back rally, it’s always interesting to see how corporate directors are acting toward their own shares. It’s no secret that corporate insiders…
The top analyst upgrades, downgrades and initiations seen on Thursday include Chevron, First Data, JD.com, MongoDB, PG&E, Rite Aid, Tilray and Vodafone.
La Jolla Pharmaceutical and Sarepta Therapeutics are among seven biotech stocks that have seen some notable insider trading recently.
Trey Thoelcke The include top analyst upgrades, downgrades and other research calls from Wednesday Akamai Technologies, Apple, AutoZone, Dropbox, Electronic Arts, Ford, Kinder Morgan, Pandora Media, Procter & Gamble and Shopify.
Sarepta Therapeutics shares skyrocketed on Tuesday after the firm presented positive preliminary results from its midstage Duchenne muscular dystrophy trial.
Chris Lange The top analyst upgrades, downgrades and other research calls from Friday included AMC, Alkermes, Echostar, Kohls, L Brands, US Bancorp and Sarepta Therapeutics.
These four top Suntrust biotech picks for 2018 all have the potential for big upside moves if they do indeed exceed first-quarter expectations.
The top analyst upgrades, downgrades and other research calls from Tuesday include AMD, Altice, Century Aluminum, Cerner, Chipotle, Cigna, GE, Micron and Noble Energy.
The top analyst upgrades, downgrades and other research calls from Friday include BioMarin, CSX, Kinder Morgan, Microsemi, Splunk, U.S. Steel and Walmart.
The top analyst upgrades, downgrades and other research calls from Wednesday include Callaway Golf, Capital One, Sarepta Therapeutics, Tesla, UnitedHealth and Wayfair.
A new RBC report is reasonably positive on the biotech sector for the coming year. These eight top picks for 2018 all have the potential for big upside moves.
